Data from the National Lung Screening Trial (NLST) showed a comparable survival benefit of smoking cessation and screening 1 . However, other risk factors for lung cancer exist and their identification and regulation also play an important role in the burden of lung cancer. Particulate matter of 10 or less micrometres (PM 10 ) and fine particles (PM 2.5 ) have recently been associated with an increased risk of lung cancer, particularly adenocarcinoma, in a large European cohort 2 and also in China, where the spatial variation of fine particles PM 2.5 was correlated with an increase in lung cancer mortality 3 . The commitment of healthcare professionals to social awareness and patient advice as well as the engagement of healthcare organizations in the regulation of these and other environmental and occupational risk factors continuously updated by the International Agency for Research on Cancer is of utmost importance for controlling the burden of lung cancer worldwide.
CANCER SCREENING
Results from the NLST comparing low-dose computed tomography (LDCT) with chest X-ray showed a 20% reduction in mortality from lung cancer and a 6.7% reduction in death from any cause with LDCT screening, leading the US Preventive Services Taskforce to recommend annual LDCT screening for lung cancer in adults from 55 to 80 years-old who have a 30 pack-year smoking history and currently smoke or have quit within the last 15 years or if comorbidity develops that limits curative surgery or life expectancy 4 .
In Europe, several randomized controlled trials (RCT) have been conducted comparing LDCT with no screening. Like the NLST trial, Detection and Screening of Early Lung Cancer by Novel Imaging Technology and Molecular Assays (DANTE), Italian Lung cancer Computed Tomography screening trial (ITALUNG) and German Lung Cancer Screening Intervention Trial (LUCI) used a diameter-based protocol for nodule measurement; whereas Danish Lung Cancer Screening Trial (DLCST), UK Lung Cancer Screening (UKLS), Multicentric Italian Lung Detection study (MILD) and Dutch acronym for the Dutch-Belgian Randomized Lung Cancer Screening Trial (NELSON) used a volumetry-based ( Fig. 1) protocol which has been shown to be superior 5 . Previous European trials are too small to detect differences in mortality and therefore results on mortality reduction in this setting 19 ).
will need to be pooled with the upcoming results of the NELSON. Other questions such as the time lapse between rounds, radiologic criteria concerning nodule segmentation, as well as the management of the newly detected nodules during follow-up -which occurred in 5-7% of individuals at each round and proved to have a higher probability of malignancy in the NELSON trial-are still to be determined 6, 7 . Furthermore, the application of risk models has proven to better identify the high-risk population that could benefit from screening, with improvements in both the effectiveness and the efficiency of the program 8, 9 .
In this sense, the addition of biomarker testing in different tissues such as airways epithelium, sputum and blood might further aid in identifying the target population. Cumulative data on non-coding RNAs suggests their involvement in lung cancer development and progression [10] [11] [12] . Future progress in this field, linked to the bioinformatic analysis of the growing number of reported microRNAs and long non-coding RNAs, could help better identify high-risk patients 13 . Finally, the availability of expert healthcare professionals to ensure not only adherence regarding selection and data collection but also to provide comprehensive smoking cessation counselling, adequate patient information and care when uncertainty is generated, as well as expertise in diagnosis and treatment when early lung cancer is detected, also determine the quality of a screening program 14 .
DIAGNOSTIC AND THERAPEUTIC BRONCHOSCOPY
In the endoscopy field, 2016 has provided different papers in which techniques expanding their usual anatomic limits to achieve a better diagnosis and staging of lung cancer were presented. Regarding treatments, novel procedures are being explored for peripheral lesions while more evidence is given for central airway obstruction recanalization.
Diagnosis
Transparenchymal nodule access (TPNA) is a new bronchoscopic technique that could be especially useful for those lesions smaller than 3 cm and without the bronchus sign (the visualization of a bronchial lumen reaching the nodule in the chest CT). This technique differs completely from the established methods (radial endobronchial ultrasound [EBUS], Virtual Navigation, Electro Magnetic Navigation and ultrathin scopes), since it reaches the nodule via the lung parenchyma instead of taking a purely endobronchial path. Harzheim et al. 15 present the first feasibility and safety study in an endoscopic unit. Six patients were recruited and a tunnel pathway (mean length 29 mm) to the nodule was created in 5 patients. Two pneumothoraces were diagnosed by chest X-ray though only one required drainage. All samples were positive for this technique.
Staging
The meta-analysis in Korevaar et al. 82 demonstrates that the combined endoscopic ultrasound staging approach is definitively the best option for obtaining the broadest possible sampling of mediastinal lymph nodes. On average, the addition of transoesophageal endoscopic ultrasound (EUS) to EBUS increased sensitivity by 0.12 (95% confidence interval EBUS can also obtain tissue samples from the left adrenal glands with a transgastric approach 16 , as well as with a transvascular approach, through the pulmonary artery and aorta 17 , with no complications.
Treatment
As the diagnostic yield of bronchoscopy improves with the incorporation of new endoscopic techniques, treatment options are also being considered. One of the latest is vapour ablation. In this pilot study in five healthy pigs, Henne et al 18 , demonstrated that a uniform field of necrosis following vapour administration into the subsegment of the anatomical boundary was achieved without major complications.
Although the interventional management of malignant central airway obstruction is well established, its impact on survival and quality of life (QoL) has not been studied extensively. Tumour debulking with any of the available methods (laser, electrocautery, cryoextraction...), and airway stabilization with stents when required (self-expandable metal or silicone), is the cornerstone of the treatment of critical airway stenosis. As a RCT with or without endoscopic treatment is unethical in this group of patients, any evidence is well appreciated. Stratakos et al. 19 Tables 1 and 2 ).
With regard to the T component, the way that its size should be measured is specifically addressed. The maximum dimension of the solid component or the invasive component is used to assign the T category. However, the maximum dimension of the ground glass or lepidic component should also be recorded. It is worth highlighting that when multiple T descriptors are applicable to a tumour, the highest T category should be chosen.
SURGERY Survival
Strong evidence published this year reinforces the known variables associated with better outcomes for patients undergoing surgery. Patient selection, a hospital's surgical volume and the tumour board's adherence to guidelines are among them. 
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Reproduced with permission from Detterbeck FC et al. 20 .
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Collaborative research
A large pool of subjects from the European Society of Thoracic Society (ESTS) database (2007-2015) was used to build risk models for morbidity (EuroLung1) and mortality (Euro Lung2). An aggregate score was created that stratified the patients into six classes of incremental mortality risk (Table 3) 21 .
Some of these variables, such as pulmonary function, can be modified before surgery. The systematic review and metaanalysis performed by Sebio et al. 22 , demonstrated that FVC and FEV 1 were significantly enhanced following preoperative exercise training. In comparison with the patients in the control groups, patients in the experimental groups spent fewer days in As guideline compliance is strongly associated with survival, other bodies, apart from national societies, should be involved to improve adherence. 20 .
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Air leak
Attaar et al. 25 have described a clinical prediction model for prolonged parenchymal air leaks (> 5 days) after pulmonary resection (Fig. 3) . Each variable was associated to a score and patients were then stratified into three risk groups with a monotonic increase: low (≤ 25 points), intermediate (26) (27) (28) (29) and high (≥ 30) risk groups, with an incidence of 2.0, 8.9 and 19.2%, respectively.
Patient-centred outcomes
The first step towards patient-centred outcomes has been already taken with the publication of the International Consortium for Health Outcomes Measurement. Through a modified Delphi method, Mak et al. 26 defined an international consensus recommendation of the most important outcomes for lung cancer patients, including time from diagnosis to treatment, acute and major complications of treatment, quality of life, survival and cause of death and finally, quality of death (duration of time spent in hospital at end of life, and where patient died). This set of recommendations must now be validated and implemented in a pilot study.
Robots
Publications on robotic surgery have accumulated in the last decade. However, controversy remains about the application of robotic surgery, ). * Zubrod score corresponds to the rating of quality of life of the Group of Eastern Cooperative Oncology (ECOG) in cancer patients, also known as performance status (PS). Http://ecog-acrin.org/ resources/ecog-performance-status. BMI: body mass index. FEV 1 : forced expiratory volume in the first second.
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together with a lack of well-established evidence. Louie et al. 27 have published a comparative study based on the Society of Thoracic Surgeons Database in the United States of America for clinical Stage I and II NSCLC. Robotic lobectomies were longer (median 186 versus 173 minutes; p < 0.001) but more patients had hospital stays of less than 4 days (48 versus 39%; p < 0.001). The rest of intra-operative measurements and all post-operative outcomes were similar. Thus, based on this retrospective comparative study, it seems that robotic surgery is equal, but not clinically superior to video-assisted thoracic surgery (VATS).
PHARMACOLOGICAL TREATMENTS Early stages
In order to shift treatment paradigms from the advanced to the adjuvant setting, biologic agents have also been investigated in radically resected patients, without achieving any advantage for bevacizumab and erlotinib in unselected populations. However, an improvement in disease-free survival (DFS) was observed with erlotinib in epidermal growth factor receptor (EGFR) mutation positive patients (without reaching statistical significance), paving the way for currently ongoing trials testing EGFR-tyrosine kinase inhibitors (TKIs) in resected patients [NCT01405079, NCT01996098, NCT02125240] 28 .
Aiming at treatment personalization, results from an Italian phase III randomized adjuvant customized chemotherapy trail [ITA-CA] exploring putative predictors of chemotherapy sensitivity or resistance are eagerly awaited.
Another intriguing strategy in the adjuvant setting exploits the potential of harnessing the immune system to achieve a complete clearance of residual tumour cells. In this context, a large phase III vaccination trial in stage IB-IIIA resected patients expressing melanoma-associated antigen 3 (MAGE-A3) failed to improve DFS 29 . Immune checkpoint inhibitors are currently also being tested in resected patients, following the results obtained in the advanced setting [NCT02486718, NCT02273375, NCT02504372].
In order to maximize treatment personalization in completely resected NSCLC patients, the U.S. National Clinical Trial Network is currently conducting a prospective multi-arm adjuvant trial [ALCHEMIST -NCT02201992, NCT02193282, NCT02194738] in which treatment allocation is based on the genomic features of each tumour. After completing standard adjuvant treatment, patients are randomized, based on the presence of anaplastic lymphoma kinase (ALK) rearrangements, EGFR mutations or the absence of both, to either placebo or crizotinib, erlotinib or nivolumab, respectively. Moreover, tumour genomics will be studied in greater depth in order to find any new predictive and prognostic factors that may emerge.
For the vast majority of Stage III NSCLC patients, standard therapy requires a multimodality therapeutic approach. Unresectable disease should preferentially be treated with concomitant chemo-radiotherapy (cCTRT), the most commonly used regimen being cisplatin with etoposide. Randomized trials testing modern platinum-based doublets, such as cisplatin plus pemetrexed and cisplatin plus vinorelbine, have failed to demonstrate superiority over that doublet, even though the toxicity profile appeared to be better with new agents 30, 31 . 
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major information breakthrough in this field was reported at the European Society of Medical Oncology (ESMO) meeting in September 2016. A small study presented by Forde et al. 32 reported 7 pathologic responses with less than 10% of tumour viable cells among 18 patients with resectable NSCLC treated with 2 cycles of neoadjuvant nivolumab therapy. When confirmed in a larger population, these data could open the door to a new series of studies in locally advanced NSCLC.
Advanced NSCLC treatment
In the last decade, the evidence that histology should guide the treatment decision making process, followed by the introduction of targeted agents for specific lung cancer populations harboring abnormally activated oncogenic introduced a personalized approach into lung cancer treatment. More recently, emerging knowledge about some of the mechanisms that govern the complex interaction between tumour cells and the host immune system, prompted a re-discovery of immune-oncology in lung cancer treatment, as well as in other tumours 33 .
Oncogene-driven NSCLC EGFR mutatEd NSCLC
First-line treatment of patients with advanced EGFR-mutation positive NSCLC is based on TKIs. A randomized phase II trial comparing a first-versus a second-generation EGFR TKI (gefitinib and afatinib, respectively) in this setting failed to demonstrate any difference in OS between the two drugs, even though afatinib treatment increased both progression-free survival (PFS) and time to treatment failure (TTF) 34, 35 . As of today, the agent of choice for first-line treatment in EGFR mutated patients is mainly based on the physician's expertise with different molecules and their different toxicity profiles.
Turning now to second-line treatments, since approximately 50% of patients develop resistance to first-and second-generation TKIs through a specific secondary EGFR mutation, T790M targeted agents have been developed in order to overcome this mechanism. Among them, osimertinib (previously known as AZD9291) represents the current standard of care in advanced EGFR-mutated T790M-positive NSCLC patients who progressed to first-line EGFR TKIs after the results of an AURA 3 randomized phase III trial 36 . This study randomized 419 T790M-positive (as assessed on tumour biopsy) to receive either osimertinib 80 mg once daily or platinum (cisplatin or carboplatin) plus pemetrexed chemotherapy. Osimertinib significantly prolonged PFS as compared to chemotherapy (10.1 versus 4.4 months; HR: 0.30; 95% CI: 0.23-0.41; p < 0.001); moreover, osimertinib treatment significantly enhanced the objective response rate (ORR) (71 versus 31%; odds ratio 5.39; 95% CI: 3.47-8.48; p < 0.001) and results in less G3 and 4 adverse events (AEs) (23 versus 47%). In the light of these results, obtaining a second biopsy as the disease progresses seems to be crucial. However, this can prove difficult due to the location of the progressing site or to patient's performance status.
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The introduction of a so-called "liquid biopsy" represented a turning point in this clinical scenario and, even though a standardized method for the detection of EGFR mutations in plasma is currently lacking, results from ancillary studies in patients treated with third-generation EGFR TKIs report a sensitivity of between 51 and 70%, depending on the assay, and a specificity of approximately 77% [37] [38] [39] . Taken all together, these data suggest the reliability of plasma genotyping in this patient population, especially when a positive result is found. In contrast, in patients with a negative plasma result, a tissue biopsy is mandatory before considering them to be "truly" negative.
aLK-REaRRaNGEd NSCLC
ALK-rearrangements are detected in approximately 5% of NSCLC. Along with crizotinib, the first targeted agent approved for the treatment of this lung cancer population, in recent years many other ALK inhibitors have entered into clinical trials. Many of them are characterized by a higher penetration in the central nervous system (CNS) than their progenitor, and some of them are active against secondary ALK mutations leading to crizotinib resistance.
Alectinib is a second-generation ALK TKI that demonstrated activity in both crizotinib-naive and pretreated patients in phase II trials 40 .
Results from a phase III randomized trial of alectinib versus crizotinib in Asian ALK-inhibitors naive advanced ALK-positive NSCLC patients demonstrated an impressive alectinib activity in terms of objective RR as compared to crizotinib (ORR by independent review 91.6 versus 78.9%) with a median PFS not reached versus 10.2 months in the experimental and control arm, respectively (HR: 0.34, 95% CI: 0.17-0.71; p < 0.0001) 41 . Results from a twin study conducted in caucasians are awaited soon.
Another second-generation ALK inhibitor, ceritinib, which is already registered by the U.S. Food and Drug Administration (FDA) for patients progressing or intolerable to crizotinib, proved to be superior to platinum plus pemetrexed chemotherapy in previously untreated ALK-rearranged NSCLC, increasing median PFS by over 8 months (16.6 versus 8.1 months; HR: 0.55, 95% CI: 0.42-0.73; p < 0.001) in a phase III trial 42 .
The same agent proved to significantly increase mPFS as compared to single-agent chemotherapy in ALK-rearranged advanced NSCLC patients previously treated with chemotherapy and crizotinib (5.4 versus 1.6 months; HR: 0.49; 95% CI: 0.36-0.67; p < 0.001). In this phase III trial, ceritinib treatment led to a higher RR and disease control rate (DCR) and a significant improvement in lung cancer symptoms and overall health status 43 .
Two other ALK inhibitors (brigatinib and lorlatinib) showed promising activity in crizotinib pre-treated ALK-rearranged patients and one of them, brigatinib, received a breakthrough therapy designation by the FDA in October 2014 for crizotinib-resistant ALK-rearranged NSCLC 44, 45 . Of note, both agents are highly active even in patients with CNS disease.
Unlike EGFR-mutated disease, crizotinib resistance mechanisms are extremely heterogeneous as there is no single dominant secondary mutation such as T790M. Importantly, different new generation agents seem to be active against specific mutations, possibly leading in the near future to a tailored approach based on each
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OthER ONCOGENE-dRivEN NSCLCS
Besides EGFR and ALK, many other genes are emerging as potential targets in NSCLC treatment. Among them, ROS1 rearrangement already has its own FDA-approved targeted agent, crizotinib 48 following the results of an expansion cohort of a Profile 1001 trial in which ROS1-positive patients achieved a 72% response rate with a median duration of response of 17.6 months 49 . Even if this alteration is rare, accounting for approximately 2% of NSCLC, many ongoing studies are testing new inhibitors in this specific subgroup of patients and even here resistance mechanisms, such as the G2032R mutation, are increasingly being reported 50 .
Rearranged during transfection (RET) gene fusions have been reported in 1% of NSCLC, especially in adenocarcinomas, the most common partner gene being KIF5B, which accounts for 90% of cases 51 . Ongoing studies are evaluating different targeted agents (cabozantinib, vandetanib, lenvatinib, apatinib, ponatinib, RXDX-105) in this lung cancer subgroup. However responses seem to be much lower when compared to other oncogene-addicted NSCLC populations [52] [53] [54] . Neurotrophic tyrosine kinase (NTRK)-1 oncogenic fusions have been reported in 3.3% of lung adenocarcinomas that were negative for other common driver mutations and several trials with specific inhibitors are ongoing. One of these agents, entrectinib, was granted FDA Orphan Drug designation for the treatment of Tropomyosin kinase (Trk)A, TrkB-, and Trk-C-positive NSCLC and colorectal cancer patients 54 . c-MET is a receptor-tyrosine kinase whose aberrant activation in lung cancer could be due to MET gene amplification (2-4%) 55 or exon 14 skipping mutations (3-4%) 56 . Gene amplification could also mediate secondary resistance in up to 20% of EGFR-mutated NSCLC patients treated with EGFR TKIs, as well as some ALK-rearranged ones.
Early results from phase II of a phase IB/II study exploring double inhibition with an EGFR TKI and captmatinib, a selective c-MET inhibitor, in MET-amplified EGFR-mutated NSCLC progressing to first-line EGFR TKI, showed a promising 80% DCR 57 . Additionally, capatinib, as well as other MET inhibitors, are currently being investigated in patients with MET exon 14 mutations (for review see reference 50 ).
Kirsten rat sarcoma (KRAS) mutations occur in up to 25% of lung adenocarcinomas, mainly involving codons 12 and 13. These mutations are usually mutually exclusive with ALK and EGFR alterations and frequently associated with smoking habits. Selumetinib is an orally available inhibitor of MAPK/Erk kinase (MEK), a downstream molecule in the KRAS activating pathway and proved to significantly increase both ORR and PFS in a randomized phase II trial in KRAS-mutated advanced NSCLC, when given in association with docetaxel. However, a phase III trial failed to show any survival benefit by adding selumetinib to docetaxel in this population 58 .
Activating the human gen BRAF mutations, mainly V600E, are found in 1 to 4% of NSCLC, BARCELONA RESPIRATORY NETWORK especially in current or former smokers. While single-agent BRAF inhibitor strategies achieved only limited benefits with an ORR between 33 and 42% 59,60 , a phase II trial of BRAF and MEK double inhibition with dabrafenib plus trametinib in BRAF(V600E)-mutated advanced NSCLC after failure of platinum-based chemotherapy resulted in an ORR of 63% and a DCR of 79% with a mPFS of 7.9 months 61 .
Immunotherapy
The emergence of immunotherapy as an effective treatment for many solid tumours has created quite a stir in oncology, though many uncertainties need to be resolved. Checkpoint inhibitors are monoclonal antibodies (mAbs) that specifically target regulatory membrane receptors in either immune or tumour-cells. As tumour cells can exploit these receptors to evade immune system detection, these drugs aim at restoring an efficient immunologic response by blocking, for example, programmed death 1 (PD-1) receptor and its ligands, programmed death ligand-1 (PD-L1) and/or PD-L2. Many molecules directed against this axis have been developed or are currently being studied in NSCLC treatment and can be divided into two main classes: PD-1 inhibitors (nivolumab and pembrolizumab) and PD-L1 directed agents (atezolizumab, durvalumab, and avelumab).
Checkpoint inhibitors in second-line therapy
Nivolumab has been approved for the second-line treatment of advanced NSCLC following the results of two twin randomized phase III studies, Checkmate 017 and Checkmate 057, comparing nivolumab with docetaxel in platinum pre-treated advanced squamous and non-squamous NSCLC patients, respectively 62, 63 . Nivolumab significantly prolonged OS by approximately 3 months in both studies with less toxicity than chemotherapy, leading to the worldwide approval of this agent.
Pembrolizumab, another anti-PD-1 mAb, was also approved for second-line PD-L1-positive NSCLC treatment following the results of a large phase I trial, which was then confirmed by a phase II/III trial 64 .
The last FDA-approved agent in this setting is atezolizumab, a mAb directed against PD-L1. In a randomized phase II of atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR) trial, atezolizumab significantly increased median overall survival (mOS) by 3 months as compared to docetaxel (12.6 versus 9.7 months; HR: 0.73; 95% CI: 0.53-0-99; p = 0.04) in advanced, previously treated NSCLC 65 . Moreover, an increasing improvement in survival was associated with increasing PD-L1 expression (evaluated in tumour cells and/or tumour-infiltrating immune cells). A subsequent phase III randomized trial (named OAK) 66 confirmed these findings, leading to drug registration in October 2016. Table 4 reports the results of randomized phase II and III trials in pre-treated advanced NSCLC patients.
Checkpoint inhibitors in first-line therapy
Following these exciting results in secondline therapy, clinical investigation almost concomitantly moved to the first-line setting.
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Collaborative research 280 BRN Rev. 2017; 3 In 2016, the results of two phase III randomized trials in this setting were reported. In the CheckMate 026 study, nivolumab failed to improve PFS as compared to platinum-based doublet chemotherapy in untreated NSCLC patients whose tumours had a PD-L1 expression of 5% or greater 67 .
Conversely, pembrolizumab significantly increased mPFS by 4 months (10.3 versus 6.0 months; HR: 0.50; 95% CI: 0.37-0.68; p < 0.001) as compared to platinum-doublet chemotherapy in previously untreated NSCLC with a PD-L1 expression of at least 50% according to the results of a randomized phase III trial. Moreover, the estimated overall survival (OS) rate was 80.2% at 6 months with pemborlizumab compared to 72.4% for chemotherapy (HR: 0.60; 95% CI: 0.41-0.89; p = 0.005), the latter treatment being associated with more AEs of . Given these results, in October 2016, pembrolizumab was approved by the U.S. FDA as the first-line treatment of advanced NSCLC with high PD-L1 expression (at least 50%) and without EGFR activating mutations or ALK rearrangements 69 . However, it should be noted that, considering the strict eligibility criteria of the first-line pembrolizumab study, the proportion of NSCLC patients who are potential candidates for front-line pembrolizumab is estimated to be in the range of 10-15% of all patients with advanced NSCLC.
Besides PD-1 checkpoint inhibitors, PD-L1 directed agents (avelumab and atezolizumab) are also being explored in front-line therapy but, as of today, only data from phase I and II studies have been reported 70, 71 .
Toxicity
Due to their specific mechanism of action, immune checkpoint inhibitors are characterized by a new spectrum of AEs, many of them with an immune-related mechanism. They include damage to endocrine glands (thyroiditis, adrenalitis, hypophysitis), skin (rash), gastrointestinal tract (with diarrhea and colitis), lungs (pneumonitis), liver (hepatitis), and kidneys (nephritis) 72 . Even if these toxicities are usually mild (especially when compared to those seen with chemotherapy), they could be subtle in their presentation and become life-threatening when not promptly recognized and treated 73 .
Early data from combination therapies
In order to further extend these results, another active field of investigation is that of combination strategies, which can be divided into two main approaches: combinations of different immune checkpoint inhibitors and combinations of chemotherapy and checkpoint inhibitors.
The association of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and PD-1 checkpoint inhibitors seems to enhance ORR in advanced NSCLC patients, especially in those with a low PD-L1 expression on tumour cells according to the results of two cohorts of the phase I study CheckMate 012 74 . However, a higher rate of AEs was observed in the combination arms, even though they were mostly manageable.
The combination of carboplatin plus pemetrexed with or without pembrolizumab as a first-line treatment for advanced non-squamous NSCLC was evaluated in the cohort of a randomized phase II study (KEYNOTE-021) 75 . A 26% difference in RR was observed, favouring the experimental arm (55 versus 29%; 95% CI: 9-42%; p = 0.0016), and a randomized phase III trial is currently ongoing in this setting [NCT02578680]. Other combinations, such as chemotherapy doublets with a PD-L1 inhibitor with or without an anti-CTLA-4 mAb, are currently under investigation with interesting preliminary results 76 .
RADIOTHERAPY: FOCUS ON STEREOTACTIC BODY RADIOTHERAPY (SBRT)
SBRT has mainly been adopted in patients with stage I-II peripheral inoperable NSCLC. While three phase III randomized trials comparing surgery to SBRT have been started, all
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Collaborative research 282 BRN Rev. 2017;3 of them closed early due to poor accrual. A subsequent pooled analysis of data from 58 patients from two of these studies demonstrated an improved 3 years OS with SBRT as compared to lobectomy (95 versus 79%, p = 0.037), while no differences in recurrence-free survival were observed 77 .
A small randomized trial compared SBRT (66 Gy in < 3 fractions) and conventional fractionated 3D radiotherapy (70 Gy in 7 weeks) in stage I medically inoperable NS-CLC patients. No differences in OS and PFS were observed, though patients treated with SBRT reported better quality of life and less toxicity 78 .
CONCLUSIONS
The first step in lung cancer control is to identify and address the growing number of known risk factors, especially air pollution with fine particulate matter (PM 2.5 ). In addition, the development of sustainable and efficient lung cancer screening programmes could play a crucial role in reducing lung cancer mortality. Improvements in CT nodule volumetry and new bronchoscopy approaches are novel instruments to reduce uncertainty and better determine candidates for surgery. Patient and centre selection for lung cancer surgery are crucial variables for getting the best candidates. New selection mortality scores are now available, though patient-centred outcomes are increasingly discussed and are being considered for implementation in the near future. With its excellent local control rates and low morbidity, SBRT is now considered to be a curative treatment option for patients with early stage NSCLC, especially those considered medically inoperable. Ongoing phase III trials will hopefully strengthen its role in larger populations.
The continuous identification of new genomically-defined lung cancer subpopulations allowed for the design of multi-arm clinical trials that simultaneously test multiple drugs or combinations in different molecularly selected patients. These "master protocols" offer the possibility of giving to each subpopulation of patients a targeted treatment, optimizing the clinical development of personalized therapies even in small groups of patients.
Immune checkpoint inhibitors are rapidly changing our clinical practice in advanced disease management and many efforts are directed towards the identification of reliable factors for patient selection. In this context, the IASLC, together with diagnostic companies and pharmaceutical industries, is currently involved in comparing, optimizing and homogenizing different PD-L1 immunohistochemical diagnostic assays. Beside PD-L1 evaluation, other potential predictive tools such as the analysis of tumour nonsynonymous mutation burden 79, 80 as well as neo-epitope load 81 , are under investigation. In the near future, additional areas of clinical investigation for immune checkpoint inhibitors will focus on the duration of treatment, as well as on the sequencing of immunotherapy, chemotherapy and targeted therapies. Cost-effectiveness studies and long-term sustainability for health care systems are additional questions to be addressed. Last but not least, one of the biggest efforts over the coming years will be to educate the medical community, including nurses, patients and caregivers, to promptly recognize and treat immune AEs.
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